Stock Markets November 19, 2026 03:57 AM

Amneal Rockets 64% as Moderna Slides: Complex Generics Power Near-Term Gains Amid Balance-Sheet Questions

Amneal’s move into difficult-to-make generics, injectables and biosimilars drives consecutive guidance raises and a strong Q3, while cash flow and leverage remain focal points for investors

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
AMRX MRNA

Amneal Pharmaceuticals has climbed roughly 63.72% since June 1 after shifting its portfolio toward complex generics, injectables and biosimilars and securing a Competitive Generic Therapy approval for lanreotide. The company reported third-quarter revenue and margin beats and has raised full-year guidance three times, but growth has come with increased leverage and a planned inventory build that pressures operating cash flow.

Amneal Rockets 64% as Moderna Slides: Complex Generics Power Near-Term Gains Amid Balance-Sheet Questions
AMRX MRNA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Amneal’s stock climbed about 63.72% since June 1 after ProPicks AI selected it at $12.90, driven by a shift into complex generics, injectables and biosimilars and a Competitive Generic Therapy approval for lanreotide.
  • Third-quarter results beat expectations: revenue rose 10% year-over-year to $862.7 million, adjusted EPS was $0.26 (up 53%), and adjusted EBITDA increased 30% to $207 million, prompting a third full-year guidance raise on November 3.
  • Balance-sheet dynamics are a concern: operating cash flow guidance was reduced to $325 million to $375 million due to an inventory build, and net leverage rose to 3.0 times adjusted EBITDA after the Kashiv acquisition, with 3.6 times expected at year-end.

Overview

Amneal Pharmaceuticals has emerged as a notable outperformer in 2026’s mid-cap landscape, posting a run of gains that contrasts with turbulence at higher-profile biotech names. Moderna has plunged 16.8% in the week to close at $206.80, while Amneal trades at $21.12, up 63.72% since InvestingPro’s ProPicks AI flagged the stock at $12.90 on June 1. The gap in investor appetite highlights differing exposures: binary pipeline risk for some biotech players versus marketed, revenue-generating franchises for a generics specialist.

What moved the stock

The share-price appreciation follows concrete commercial and operational developments. Amneal is pursuing a strategy that favors complex generics, biosimilars and non-oral solid products, categories that typically have higher technical barriers to entry and fewer competitors. The company now holds the most Competitive Generic Therapy approvals in the U.S., an FDA designation given to generics facing little or no competition. Non-oral solid products have grown to represent 59% of Amneal’s Affordable Medicines mix in 2026, up from 35% in 2019.

A pivotal moment came with the FDA approval of Amneal’s generic of Somatuline Depot, lanreotide, on September 18. That approval carried a Competitive Generic Therapy designation and Amneal launched the product immediately using its internal, large-scale manufacturing capacity. Somatuline Depot recorded $983 million of U.S. sales in the 12 months through July 2026. Amneal reported lanreotide contributing about $7 million in the third quarter, and management expects multiple times that contribution in the fourth quarter while targeting a 30% to 40% market share.

Quarterly performance and guidance

Third-quarter results offered tangible evidence that the portfolio transition is affecting the income statement. Revenue rose 10% year-over-year to $862.7 million, topping the consensus estimate of $812.1 million. Adjusted EPS came in at $0.26, a 53% increase and higher than the $0.23 estimate. Adjusted EBITDA increased 30% to $207 million, with margins expanding 370 basis points to 24.0%.

Management raised full-year guidance on November 3 for the third time, setting revenue between $3.15 billion and $3.25 billion, adjusted EBITDA of $800 million to $815 million, and adjusted EPS of $1.04 to $1.08.

Capital allocation, cash flow and leverage

While operating performance improved on an adjusted basis, cash generation has lagged the pace of operational growth. Amneal narrowed its operating cash flow guidance to $325 million to $375 million from a prior range of $350 million to $400 million, citing a purposeful inventory build to support growth products and collections shifting into the first quarter of 2027.

The August acquisition of Kashiv’s biosimilar business expanded Amneal’s end-to-end capabilities in R&D, manufacturing and commercialization and allowed the company to retain 100% of the profits from its generic lanreotide. That acquisition lifted net leverage to 3.0 times adjusted EBITDA at the end of the third quarter, with management expecting 3.6 times at year-end and targeting net leverage below 3 times by 2028.

On a GAAP basis, Amneal posted a net loss of $21.7 million in the third quarter, driven by acquisition and integration costs related to Kashiv, property losses and legal charges.

Analyst views and valuation

ProPicks AI added Amneal to its Mid-Cap Movers strategy on June 1, predating both the lanreotide approval and the third guidance raise. Since then, several sell-side firms have provided coverage, with JPMorgan and UBS rating the stock Buy at $25, Oppenheimer at $27, Leerink at $23 and Piper Sandler at $21. DA Davidson rates the stock Hold. The median 12-month analyst target stands at $24.29 inside a range of $20 to $28, which sits above the current trading price of $21.12.

By contrast, InvestingPro’s Fair Value model estimates intrinsic value at $17.16 per share, a more conservative assessment that places the current market price above the modelled intrinsic figure. Analysts forecast EPS increasing from $1.04 in fiscal 2026 to $1.28 in fiscal 2027 and $1.50 in fiscal 2028, implying a multiple of about 20.3 times this year’s estimate based on the current share price.

Business model and competitive positioning

Amneal’s revenue model emphasizes products that are difficult to replicate and slow to win regulatory approval, which tends to constrain competition and support higher margins for successful launches. The company’s Competitive Generic Therapy approvals and its shift into non-oral solid and injectable products are consistent with a strategy to move away from commoditized generics toward higher-barrier assets.

Management’s target for lanreotide market share and the in-house manufacturing scale to launch the product immediately suggest operational readiness to capitalize on approvals when they arrive. The Kashiv acquisition similarly positions Amneal to capture a larger share of biosimilar economics by internalizing R&D, production and commercialization activities.

Near-term catalysts and what to watch

Upcoming launches are key to sustaining growth. Management has guided that an XOLAIR biosimilar depends on active patent settlement discussions, with a launch guided for late in the second half of 2027, and denosumab is expected in mid-2027. These launches represent potential revenue drivers but are not certain events at this stage and depend on ongoing legal and regulatory developments.


Conclusion

Amneal’s share-price strength reflects a business moving toward complex generics and biosimilars that are already contributing to sales and margins. Third-quarter results and consecutive guidance raises provide evidence that the company’s strategy is translating into improved adjusted earnings. At the same time, investors must weigh rising leverage and a temporary drag on operating cash flow from strategic inventory building against the near-term revenue wins and analyst optimism.

For market participants, the contrast with a name like Moderna underscores the difference between pipeline-driven biotech valuation volatility and earnings visibility tied to marketed pharmaceuticals. Amneal’s path forward will hinge on the timely execution of scheduled launches, conversion of approvals into sizeable market share and the company’s ability to convert adjusted profits into comparable cash flow while managing its balance sheet targets.

Risks

  • Future growth depends on product launches that are not guaranteed. The XOLAIR biosimilar requires patent settlement discussions to conclude before a late-2027 launch, and denosumab is targeted for mid-2027 — both dates are guidance rather than confirmed outcomes. This affects healthcare and pharmaceutical revenue forecasts.
  • Cash generation has lagged adjusted earnings. Amneal trimmed operating cash flow guidance to reflect inventory build and collections timing, which introduces short-term liquidity and working-capital risk affecting operations and financial flexibility.
  • Rising leverage following the Kashiv acquisition increases refinancing and balance-sheet risk. Net leverage was 3.0 times adjusted EBITDA at quarter-end and is expected to reach 3.6 times at year-end, creating sensitivity to interest rates and refinancing markets in the financial sector.

More from Stock Markets

Toyota Issues Recall for 314,029 U.S. Vehicles Over Potential Takata Air Bag Hazard Nov 19, 2026 Palantir’s Best Quarter Yet Still Sparks a Stock Sell-Off Nov 19, 2026 Dell’s $95 Billion AI Backlog Tests Low-Margin Hardware Economics Nov 19, 2026 Bloom Energy Faces Market Scepticism Despite Rapid AI-Driven Order Flow Nov 19, 2026 Evotec Shares Jump After FDA Clears Second IND From BMS Collaboration Nov 19, 2026